Liquidia Corporation - Common Stock (LQDA)
Frequently Asked Questions About Liquidia Corporation - Common Stock (LQDA)
Has Liquidia Corporation received any regulatory approvals?
Yes, Liquidia Corporation received approval from the U.S. Food and Drug Administration (FDA) for its product LIQ861, which is an inhaled formulation of treprostinil for the treatment of pulmonary arterial hypertension. This approval marks a significant milestone for the company, validating its technology and expanding treatment options for patients.
How does Liquidia engage with stakeholders?
Liquidia Corporation engages with stakeholders, including investors, healthcare professionals, and patient advocacy groups, through various channels, including investor presentations, scientific conferences, and community outreach initiatives. The company strives to maintain transparency and open communication to keep stakeholders informed of its progress and developments.
How does Liquidia ensure the quality of its products?
Liquidia Corporation ensures the quality of its products by adhering to rigorous regulatory standards in the pharmaceutical industry. The company implements comprehensive quality control systems and processes at every stage of product development, from the design and manufacturing of drug particles to clinical trials and market release.
How does Liquidia plan to fund its operations?
Liquidia Corporation plans to fund its operations through a combination of equity financing, partnerships, and revenue generated from its product sales. The company actively seeks collaborations with other pharmaceutical companies and stakeholders to support its research and development efforts while ensuring sustainable growth.
How does the financial performance of Liquidia Corporation look?
As a clinical-stage company, Liquidia Corporation may not yet generate consistent revenues, and its financial performance is heavily influenced by the progress of its clinical trials and regulatory approvals. Investors should review the company's financial statements, including revenue, expenses, and cash flow, to assess its financial health and outlook.
Is Liquidia Corporation a publicly traded company?
Yes, Liquidia Corporation is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol LQDA. The company went public in 2018, providing investors with the opportunity to participate in its growth and development efforts in the biopharmaceutical industry.
What are Liquidia's lead product candidates?
Liquidia's lead product candidate is LIQ861, which is an inhaled formulation of treprostinil, being developed for the treatment of pulmonary arterial hypertension (PAH). The company is also involved in developing other therapeutics using its PRINT technology that may target various diseases.
What are the risks associated with investing in Liquidia Corporation?
Investing in Liquidia Corporation involves various risks, including the inherent uncertainties of drug development, regulatory approval processes, market competition, and the potential for financial volatility. Investors should consider these factors and conduct thorough research before making investment decisions.
What are the upcoming milestones for Liquidia Corporation?
Upcoming milestones for Liquidia Corporation include advancing its clinical pipeline, which may involve the initiation of new clinical trials for its product candidates, expanding its product portfolio, securing commercial partnerships, and achieving further regulatory approvals for its therapies to enhance patient access and drive growth.
What diseases does Liquidia target?
Liquidia Corporation primarily targets diseases in the pulmonary space, with a focus on pulmonary arterial hypertension (PAH). The company aims to develop therapies that can improve patient outcomes in this and potentially other therapeutic areas using its PRINT technology.
What does Liquidia Corporation do?
Liquidia Corporation is a clinical-stage pharmaceutical company that focuses on the development of particle engineering technology to create innovative therapies for serious diseases. The company utilizes its proprietary PRINT® (Particle Replication in Non-woven Templates) technology to design and manufacture engineered drug particles with precise properties, enabling the targeted delivery of drugs, particularly in the field of pulmonary medicine.
What is Liquidia's approach to innovation?
Liquidia Corporation's approach to innovation is centered around its proprietary PRINT technology, which allows for precise control over drug particle characteristics. The company emphasizes research and development to continuously improve its formulations and explore new therapeutic applications, fostering a culture of creativity and scientific inquiry.
What is the mission of Liquidia Corporation?
Liquidia Corporation's mission is to improve the lives of patients through the development of innovative therapies that meet unmet medical needs. The company is committed to leveraging its advanced particle engineering technology to create safe and effective treatments for serious diseases, particularly in the field of pulmonary medicine.
What is the potential market size for Liquidia's products?
The potential market size for Liquidia's products, especially in the area of pulmonary arterial hypertension, is significant. The PAH market is projected to reach multiple billions of dollars globally, driven by the increasing prevalence of the condition and the need for effective treatments. Liquidia's innovative therapies aim to capture a portion of this expanding market.
What is the PRINT technology that Liquidia uses?
PRINT technology, which stands for Particle Replication in Non-woven Templates, is a proprietary platform developed by Liquidia. It allows for the precise design and manufacturing of particles at the nanoscale, enabling the creation of drug formulations with tailored release profiles and improved efficacy. This technology can be applied to a range of therapeutic areas.
What is the significance of Liquidia's collaboration partnerships?
Liquidia Corporation's collaboration partnerships are significant because they enable the company to leverage external expertise and resources to advance its research and development efforts. Strategic alliances with other pharmaceutical companies and research institutions can provide access to funding, knowledge, and technology, helping Liquidia to accelerate product development and enhance its market position.
When was Liquidia Corporation founded?
Liquidia Corporation was founded in 2004. Since its inception, the company has focused on leveraging its unique technology platform to develop products that address unmet medical needs, particularly in the area of pulmonary diseases and other therapeutic areas.
Where is Liquidia Corporation headquartered?
Liquidia Corporation is headquartered in Morrisville, North Carolina. The company's location in the Research Triangle area provides it with access to a robust network of academic and research institutions, facilitating innovation and collaboration in the biopharmaceutical sector.
Who are Liquidia Corporation's key competitors?
Liquidia Corporation faces competition from various biopharmaceutical companies in the pulmonary space, particularly those developing treatments for pulmonary arterial hypertension. Key competitors may include established firms that offer existing therapies as well as smaller biotech companies working on innovative solutions targeting similar indications.
Who are the key executives at Liquidia Corporation?
Key executives at Liquidia Corporation include its CEO, who leads the overall strategic direction, as well as the chief medical officer, chief financial officer, and heads of various departments such as research and development, regulatory affairs, and commercial operations. The leadership team brings extensive experience from the biopharmaceutical industry.
What is the current price of Liquidia Corporation - Common Stock?
The current price of Liquidia Corporation - Common Stock is 14.52
When was Liquidia Corporation - Common Stock last traded?
The last trade of Liquidia Corporation - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Liquidia Corporation - Common Stock?
The market capitalization of Liquidia Corporation - Common Stock is 1.12B
How many shares of Liquidia Corporation - Common Stock are outstanding?
Liquidia Corporation - Common Stock has 76.79M shares outstanding.